In this QCast episode, co-hosts Jullia and Tom explore functional service provision and why it remains such a widely used outsourcing model in clinical development. They clarify what FSP means in practical terms: outsourcing a defined function, or part of a function, while the sponsor retains overall direction and oversight. The conversation focuses on where this model tends to matter most, including situations where internal teams are stretched, specialist expertise is needed in one area of delivery, or sponsors want more control over how individual functions are run across a study or portfolio.
They also discuss how FSP differs from full-service outsourcing, why that distinction matters in day-to-day operations, and what tends to determine whether the model works well. Along the way, Jullia and Tom highlight common pressure points such as vague scope, blurred accountability, weak communication routes, and poor system alignment between teams. They also look at the practical benefits sponsors often seek, including more flexible capacity, stronger functional continuity, and access to delivery teams that can integrate closely with sponsor processes while supporting quality, visibility, and oversight.
🎧 Listen to the Episode:
Key Takeaways
What Functional Service Provision Means and Why Sponsors Use It
Functional service provision refers to outsourcing a defined function, or part of a function, rather than transferring responsibility for an entire study. Sponsors often use this model when they need targeted support in areas such as data management, statistical programming, pharmacovigilance, monitoring, or other specialist functions. Its value comes from giving sponsors access to external expertise and scalable capacity while allowing them to retain closer control over priorities, processes, and delivery oversight.
How FSP Differs from Full-Service Outsourcing
A full-service model typically places end-to-end operational responsibility for a study, or a major part of it, with the provider. Under FSP, the work is split by function, which means the sponsor usually keeps more direct responsibility for coordination across teams and for overall governance. That structure can provide more flexibility and better alignment to sponsor systems, but it also means the sponsor needs clear boundaries, clear reporting routes, and a well-defined operating model from the start.
What Makes the Model Work in Practice
FSP tends to work best when scope is clearly defined, hand-offs are well understood, and governance is built in early. Sponsors need enough visibility into status, risks, and functional performance to maintain effective oversight, especially when multiple teams or systems are involved. Strong implementation usually depends on realistic workload planning, functional depth from the provider, aligned technology and reporting processes, and communication routes that support quick escalation when issues cross functions.
Full Transcript
Jullia
Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.
Tom
I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.
Jullia
Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.
Tom
Today we’re getting into functional service provision, or FSP. It comes up a lot in outsourcing conversations, but people still use it to mean slightly different things. So, Jullia, when someone says FSP in a clinical development setting, what should they understand straight away?
Jullia
Well at the simplest level, FSP means outsourcing a defined function, or part of a function, rather than handing over an entire study. The sponsor still keeps overall direction and oversight, but they bring in external capability where they need it most. That could be data management, biostatistics, statistical programming, pharmacovigilance, monitoring, medical writing, or regulatory support.
What matters is the boundary. You’re deciding what sits with the sponsor, what sits with the provider, and how the hand-offs work day to day. That’s why FSP often feels like extending an internal function, rather than handing work off at arm’s length.
Tom
So the distinction is really about structure. You’re not outsourcing everything, you’re choosing where outside support fits into the operating model?
Jullia
Yes, and that choice tends to be very practical. A sponsor might have a strong internal clinical strategy team, but need scalable programming support across several studies. Or they may want tighter control of cross-functional priorities, while still adding experienced people into one pressured area.
So you tend to see FSP used when internal teams are stretched, or when a sponsor needs expertise that’s hard to maintain at the right volume. A common scenario is a study ramping up quickly and the pinch-point isn’t the whole programme. It’s something specific, like lab data cleaning, query turnaround, site monitoring coverage, or safety case processing.
Tom
Yeah I hear a lot of people talk about outsourcing as if it’s one decision, when often the pressure is sitting in one workstream.
Jullia
Yes, and there’s more than one way to set an FSP up. Sometimes the provider takes end-to-end responsibility for one function. Sometimes you get a dedicated team aligned to the sponsor’s processes and systems. Sometimes it’s closer to staff augmentation, with individual roles added for a period.
The operating shape matters because it affects accountability, training, onboarding, and how smoothly that team can work alongside the sponsor organisation.
Tom
Now let’s stay on that for a second, because people often collapse FSP and full-service outsourcing into the same thing. What’s the cleanest way to separate them?
Jullia
Well the cleanest way is to look at accountability, coordination, and where the work is being run from. In a full-service outsourcing model, a CRO is usually taking end-to-end operational responsibility for a study or a major part of it. Project management is integrated within that provider-led structure, and the sponsor has fewer delivery interfaces to manage.
But with FSP, the delivery is split by function. The sponsor usually retains more direct control over priorities, cross-functional integration, and the overall shape of execution. Quite often the FSP team works inside sponsor systems and sponsor standard operating procedures, which helps continuity. The trade-off is that the sponsor has more to coordinate and govern.
Tom
And where does FSO fit in here? Because some teams use full-service CRO and full-service outsourcing almost interchangeably.
Jullia
So in most conversations they’re pointing to the same broad model, which is provider-led, end-to-end trial delivery. Now the useful question isn’t the label. It’s what the operating setup actually looks like. Who owns the day-to-day plan? Who is integrating the functions? Who is escalating issues? What systems are people working in? How is the contract structured?
And commercially, you often see a difference too. Full-service models are commonly milestone or unit based. FSP is often built around full-time equivalent resourcing, or another structure tied more directly to functional capacity. And that changes how teams think about flexibility, budget control, and scaling.
Tom
And what tends to go wrong there?
Jullia
Well the main problems are usually at the interfaces. If scope is vague, accountability gets blurred. If systems don’t align, people create silos. And if the sponsor hasn’t thought through communication and escalation, small delivery issues travel too slowly.
You can actually picture it quite easily. Say a dosing change needs to be reflected across data management, safety review, and reporting outputs. If those boundaries aren’t defined well, teams can lose time deciding who owns the update path. Or take site start up for example. If local execution support is outsourced but sponsor expectations on reporting cadence are unclear, the sponsor may think sites are on track until a milestone starts slipping.
Tom
So the model doesn’t remove oversight. It changes what oversight needs to look like?
Jullia
That’s right. Current guidance still expects sponsors to maintain appropriate oversight of trial-related activities carried out by service providers, so retaining control means more than keeping your name on the study. It means clear governance, quality review, issue management, and enough visibility to intervene when needed.
When FSP is set up well, sponsors can see status and risks earlier through shared systems or agreed reporting routes. That could be adverse event entry backlogs, unresolved queries, slow site activation, or missed lab reconciliations.
Tom
Then there’s also the benefits side, which is often where these conversations start. Budget, flexibility, and access to specialists are some examples. But some of those claims can sound a bit generic. Which ones actually hold up in real delivery?
Jullia
Well the good news is that a few do, consistently. One is more predictable spending when scope and resourcing assumptions are clear. Another is access to flexible capacity without the lag of recruiting internally.
Then there’s that specialist expertise you mentioned. Some functions really depend on experience and repeatable delivery capability. So if you can bring in a team that already knows how to handle the work at the right quality level, you reduce avoidable rework. Continuity matters too. Dedicated teams often hold context across studies better, which helps with handovers, training, and changing priorities.
Tom
Could you give me one concrete example of where that continuity shows up?
Jullia
So a good example is data management during a busy portfolio period. If you’ve got a ring-fenced team that already understands your edit check approach, your lab vendor conventions, and your escalation routes, they can absorb a spike in data review more smoothly. You’re not reteaching basics while the database is filling up.
Then another example is statistical programming. A dedicated team that already knows the sponsor’s shells, specifications, validation expectations, and submission rhythm tends to produce more consistent outputs with fewer avoidable resets. And that accumulated context is genuinely valuable in regulated delivery.
Tom
Now before we get too far into the upsides, what should a sponsor pressure-test when choosing an FSP partner?
Jullia
I’d start with scope. Be very specific about what is in and out. Then look at whether the provider has functional depth that matches the work you actually run, not just a broad capability statement.
After that, I’d look hard at deployment and onboarding. How do they find the right people? How quickly can they flex if demand changes? What does training look like? How will the team align to sponsor processes, systems, and quality expectations? You also need clear communication routes, escalation paths, and role clarity from the start. And for global programmes, time zones, regional execution, and local requirements need to be thought through early, because they affect how smoothly the model works.
Tom
I think that also ties into implementation. People can choose the right model, and there can still be issues.
Jullia
Absolutely. Forward planning matters more than people sometimes expect. If you don’t have a realistic view of upcoming workload, likely study starts, and where pressure is likely to land, it’s much harder to shape the right FSP arrangement. So the model ends up reacting to surprises instead of absorbing them.
Technology alignment is another big one. Teams need to agree how data will move, who owns which systems, what support model is in place, and how reporting will work. You don’t want separate functional islands where information flow gets blocked. Once an issue crosses functions, decisions slow down very quickly.
Tom
Now if someone listening is actively looking into implementing FSP, what are the practical checks they should consider?
Jullia
Three quick things. First, define the functional boundary clearly, including hand-offs and escalation points. Second, choose the model that matches the workload pattern, because stable repeatable work and volatile demand often need different setups. Third, make visibility non-negotiable, so reporting, issue management, and system alignment support real oversight from day one.
Tom
Let’s discuss one more angle before we wrap up. Now the broader market around FSP has shifted quite a bit. What are you seeing in the way sponsors are thinking about it now?
Jullia
Now the direction is towards more hybrid thinking. Sponsors are mixing models more deliberately, because trials are harder to run cleanly with one fixed outsourcing pattern across everything. Cost pressure, recruitment difficulty, operational complexity, and workload volatility are all pushing teams to be more selective about where they want full-service delivery and where they want function-specific support.
And there’s also a stronger expectation around technology. Sponsors want faster access to data, clearer reporting, and delivery models that can support dispersed teams. And as programmes spread across regions, global operating capability becomes more important. That doesn’t mean global is automatically better. It means more programmes now need delivery designs that can cope with regional variability without losing control.
Tom
And I suppose with that growth comes a familiar concern. More outsourced capacity can mean more exposure if governance is weak, especially around data handling and privacy. Does that sound right?
Jullia
Yes and that’s why the conversation has matured. The question is less whether FSP is good or bad. It’s whether the chosen model gives the sponsor enough control, clarity, and resilience for the work in front of them.
So if I had to boil it down, I’d say two things matter most. FSP works best when the function boundary is clear, and when governance is designed in early enough to support real oversight.
Jullia
With that, we’ve come to the end of today’s episode on functional service provision. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.
Tom
Thanks for tuning in, and we’ll see you in the next episode.
About QCast
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.
